Buccal Midazolam Supporting Guideline v1
... dose may be given 6 or more hours later if they have a second prolonged seizure. In clinical settings (e.g. medical facilities or hospitals) a second dose is given 10 minutes after the first if the seizure continues. Occasionally this might be advised in special circumstances in a community setting. ...
... dose may be given 6 or more hours later if they have a second prolonged seizure. In clinical settings (e.g. medical facilities or hospitals) a second dose is given 10 minutes after the first if the seizure continues. Occasionally this might be advised in special circumstances in a community setting. ...
CHF Drugs
... - If pts are receiving too much, the initial IV dose should equal or exceed their chronic daily dose. - Urine output and signs/symptoms of congestion should be serially assessed and dose adjusted accordingly to relieve symptoms, reduce volume excess, and avoid hypotension. Previously not on diuretic ...
... - If pts are receiving too much, the initial IV dose should equal or exceed their chronic daily dose. - Urine output and signs/symptoms of congestion should be serially assessed and dose adjusted accordingly to relieve symptoms, reduce volume excess, and avoid hypotension. Previously not on diuretic ...
Recommendation and Reasons
... The Canadian Expert Drug Advisory Committee (CEDAC) recommends that raltegravir not be listed at the submitted price. Reason for the Recommendation: In one double-blind randomized controlled trial in treatment-naive patients, the proportion of patients with HIV-1 RNA < 50 copies/mL, serious adverse ...
... The Canadian Expert Drug Advisory Committee (CEDAC) recommends that raltegravir not be listed at the submitted price. Reason for the Recommendation: In one double-blind randomized controlled trial in treatment-naive patients, the proportion of patients with HIV-1 RNA < 50 copies/mL, serious adverse ...
Product Monograph
... agonists. Considering the extent of use of 5-HT1 agonists in patients with migraine, the incidence of these events is extremely low. Patients with symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders should not receive RELPAX. ...
... agonists. Considering the extent of use of 5-HT1 agonists in patients with migraine, the incidence of these events is extremely low. Patients with symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders should not receive RELPAX. ...
Swine: Baytril® 100 is indicated for the treatment and control of
... In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. See ...
... In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. See ...
Atorvastatin 80 mg daily - Centre for Medicines Optimisation
... Q rating: The evidence for the efficacy and safety of atorvastatin 80 mg in patients with acute coronary syndrome or established cardiovascular disease was considered to be relatively strong, based on four randomised controlled trials comparing atorvastatin 80 mg daily with “moderate” statin therapy ...
... Q rating: The evidence for the efficacy and safety of atorvastatin 80 mg in patients with acute coronary syndrome or established cardiovascular disease was considered to be relatively strong, based on four randomised controlled trials comparing atorvastatin 80 mg daily with “moderate” statin therapy ...
TIMOPTOL-XE
... Due to its negative effect on conduction time, beta-blockers should be given with caution to patients with first degree heart block. Severe respiratory complications, including death due to bronchospasm in patients with asthma, and cardiac complications, including rarely death in association with ca ...
... Due to its negative effect on conduction time, beta-blockers should be given with caution to patients with first degree heart block. Severe respiratory complications, including death due to bronchospasm in patients with asthma, and cardiac complications, including rarely death in association with ca ...
Full Prescribing Information
... Pregnancy Category C. Polidocanol has been shown to have an embryocidal effect in rabbits when given in doses approximately equal (on the basis of body surface area) to the human dose. This effect may have been secondary to maternal toxicity. There are no adequate and well-controlled studies in preg ...
... Pregnancy Category C. Polidocanol has been shown to have an embryocidal effect in rabbits when given in doses approximately equal (on the basis of body surface area) to the human dose. This effect may have been secondary to maternal toxicity. There are no adequate and well-controlled studies in preg ...
& ● Memorandum
... Ph. D., reports that rats were tested for the effect of the ingredient on the gastrointestinal mucosa. The oral administration of single dose or repeated dose of up to 1,200 mg/kg for 30 days did not affect the integrity of the mucosal tissue, “suggesting that SAMe does not interfere with the cytopr ...
... Ph. D., reports that rats were tested for the effect of the ingredient on the gastrointestinal mucosa. The oral administration of single dose or repeated dose of up to 1,200 mg/kg for 30 days did not affect the integrity of the mucosal tissue, “suggesting that SAMe does not interfere with the cytopr ...
Salmeterol Xinafoate/Fluticasone Propionate Dry Powder for
... symptoms, reducing the use of rescue beta-II agonists, and reducing the incidence of exacerbations than either of its two component agents used alone at the same doses. Clinicians have demonstrated that using a longacting inhaled bronchodilator in combination with an inhaled corticosteroid offers si ...
... symptoms, reducing the use of rescue beta-II agonists, and reducing the incidence of exacerbations than either of its two component agents used alone at the same doses. Clinicians have demonstrated that using a longacting inhaled bronchodilator in combination with an inhaled corticosteroid offers si ...
Aubagio Prescribing Information
... AUBAGIO is not recommended for patients with severe immunodeficiency, bone marrow disease, or severe, uncontrolled infections. Medications like AUBAGIO that have immunosuppression potential may cause patients to be more susceptible to infections, including opportunistic infections. In placebo-contro ...
... AUBAGIO is not recommended for patients with severe immunodeficiency, bone marrow disease, or severe, uncontrolled infections. Medications like AUBAGIO that have immunosuppression potential may cause patients to be more susceptible to infections, including opportunistic infections. In placebo-contro ...
6/28/2012
... Specific guidelines for non-CNS disease based on severity Reduction of immunosuppression as much as possible ...
... Specific guidelines for non-CNS disease based on severity Reduction of immunosuppression as much as possible ...
Liver toxicity: the Achilles’ heel of endothelin receptor antagonist therapy? EDITORIAL
... be lower than for ambrisentan, and six cases of severe hepatitis have now been reported, four of them under the currently approved dose of 100 mg q.d. Thus, although several lines of evidence suggest that increases in aminotransferases are less common with sitaxentan than with bosentan [5, 7, 8], th ...
... be lower than for ambrisentan, and six cases of severe hepatitis have now been reported, four of them under the currently approved dose of 100 mg q.d. Thus, although several lines of evidence suggest that increases in aminotransferases are less common with sitaxentan than with bosentan [5, 7, 8], th ...
USE OF EYE DROPS IN PREGNANCY
... Aciclovir is an antiviral agent used topically for herpes simplex infections of the skin, mucous membranes and eye. Overall, the data do not show an increased risk for congenital malformations or other fetal toxicity from exposure to topical aciclovir at any time in pregnancy. Fucidic Acid There are ...
... Aciclovir is an antiviral agent used topically for herpes simplex infections of the skin, mucous membranes and eye. Overall, the data do not show an increased risk for congenital malformations or other fetal toxicity from exposure to topical aciclovir at any time in pregnancy. Fucidic Acid There are ...
Bacterial Conjunctivitis November 2011
... used as a supportive therapy with or without treatment to provide comfort and to help reduce inflammation.2 Patients should be asked to return for a follow-up visit if they have no improvement in three to four days.1 Conclusion Acute bacterial conjunctivitis is a disease that usually resolves on its ...
... used as a supportive therapy with or without treatment to provide comfort and to help reduce inflammation.2 Patients should be asked to return for a follow-up visit if they have no improvement in three to four days.1 Conclusion Acute bacterial conjunctivitis is a disease that usually resolves on its ...
cattani_essay
... tonsillitis. This antibiotic can also treat other infections such as in the Middle Ear. Occasionally, it can be used before dental procedures for patients with certain heart conditions such as artificial heart valves. Using Cephalexin before some procedures will help prevent serious bacterial infect ...
... tonsillitis. This antibiotic can also treat other infections such as in the Middle Ear. Occasionally, it can be used before dental procedures for patients with certain heart conditions such as artificial heart valves. Using Cephalexin before some procedures will help prevent serious bacterial infect ...
gau psychotropic medication guidelines
... Start: 25 mg daily for two weeks then 50 mg daily for two weeks (may increase by 100 mg per week thereafter) with a usual max dosage of 200 – 300 mg (typically divided bid). Dosage will need to be adjusted for patients taking enzyme-inducing drugs or Depakote. Starter packs are available. Typically ...
... Start: 25 mg daily for two weeks then 50 mg daily for two weeks (may increase by 100 mg per week thereafter) with a usual max dosage of 200 – 300 mg (typically divided bid). Dosage will need to be adjusted for patients taking enzyme-inducing drugs or Depakote. Starter packs are available. Typically ...
file (Parkinsons Disease Topic
... Has a shorter half-life than tolcapone Dose: 200 mg needs to be given with each dose of carbidopa/levodopa up to a maximum of 8 times/day Increase total daily “on” time by 1-2 hours Adverse effects: Brownish-orange urine, delayed onset diarrhea (no liver issues) Available in combination tablet with ...
... Has a shorter half-life than tolcapone Dose: 200 mg needs to be given with each dose of carbidopa/levodopa up to a maximum of 8 times/day Increase total daily “on” time by 1-2 hours Adverse effects: Brownish-orange urine, delayed onset diarrhea (no liver issues) Available in combination tablet with ...
National Prescribing Indicators 2015
... should be prescribed tramadol only if there are compelling reasons to do so. Tramadol should be used with caution in patients taking concomitant drugs that can lower the seizure threshold (tricyclic antidepressants, selective serotonin reuptake inhibitors [SSRIs]) (MHRA Current Problems in Pharmacov ...
... should be prescribed tramadol only if there are compelling reasons to do so. Tramadol should be used with caution in patients taking concomitant drugs that can lower the seizure threshold (tricyclic antidepressants, selective serotonin reuptake inhibitors [SSRIs]) (MHRA Current Problems in Pharmacov ...
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS
... danger of foetal renal maldevelopment. Like ACE inhibitor treatment, regimens based on ARBs reduce the risk of new onset diabetes. ...
... danger of foetal renal maldevelopment. Like ACE inhibitor treatment, regimens based on ARBs reduce the risk of new onset diabetes. ...
Lithium sulfate
... Lithium (Li) is used in psychiatry for the treatment of mania, endogenous depression and psychosis; and also for treatment of schizophrenia. Usually lithium carbonate (Li2CO3) is applied, but sometimes lithium citrate (Li3C6H5O7), lithium sulfate, or lithium oxybutyrate are used as alternatives [1, ...
... Lithium (Li) is used in psychiatry for the treatment of mania, endogenous depression and psychosis; and also for treatment of schizophrenia. Usually lithium carbonate (Li2CO3) is applied, but sometimes lithium citrate (Li3C6H5O7), lithium sulfate, or lithium oxybutyrate are used as alternatives [1, ...
Starlix - Novartis Pharmaceuticals Corporation
... Pregnancy Category C There are no adequate and well-controlled studies of nateglinide in pregnant women. It is unknown whether STARLIX can cause fetal harm when administered to a pregnant woman. STARLIX should be used during pregnancy only if the potential benefit justifies the potential risk to the ...
... Pregnancy Category C There are no adequate and well-controlled studies of nateglinide in pregnant women. It is unknown whether STARLIX can cause fetal harm when administered to a pregnant woman. STARLIX should be used during pregnancy only if the potential benefit justifies the potential risk to the ...
Seeking Insight - sun pharma advanced research company
... • A “self-dispersing” nano particle formulation of Docetaxel. Avoids “toxic” solvents used in conventional docetaxel formulations. Low excipient to drug ratio. Safe to dose up to 7.5 times higher than the conventional docetaxel in acute and sub-acute toxicity studies in 2 species. ...
... • A “self-dispersing” nano particle formulation of Docetaxel. Avoids “toxic” solvents used in conventional docetaxel formulations. Low excipient to drug ratio. Safe to dose up to 7.5 times higher than the conventional docetaxel in acute and sub-acute toxicity studies in 2 species. ...
New Drug Update 2015
... Following this presentation, pharmacists will be able to: Identify therapeutic indications and pharmacological properties of specific drugs recently approved by the ...
... Following this presentation, pharmacists will be able to: Identify therapeutic indications and pharmacological properties of specific drugs recently approved by the ...
Page 1 of 20 Nabumetone Tablets USP 500 mg and 750 mg Rx only
... 0.8% (95% CI; 0.3%, 1.3%) at 2 years. In patients with active peptic ulcer, physicians must weigh the benefits of therapy with nabumetone against possible hazards, institute an appropriate ulcer treatment regimen and monitor the patients’ progress carefully. NSAIDs should be prescribed with extreme ...
... 0.8% (95% CI; 0.3%, 1.3%) at 2 years. In patients with active peptic ulcer, physicians must weigh the benefits of therapy with nabumetone against possible hazards, institute an appropriate ulcer treatment regimen and monitor the patients’ progress carefully. NSAIDs should be prescribed with extreme ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.